The heterozygous Sod2+/- mouse: modeling the mitochondrial role in drug toxicity

Drug Discovery Today

Volumn 13, Issue 21-22, 2008, Pages 982-988

  Boelsterli, Urs A ^a   Hsiao, Chin Ju J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALANINE; ANTIOXIDANT; APOPTOSIS SIGNAL REGULATING KINASE 1; CATALASE; CYTOCHROME C; CYTOSINE; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; HYDROGEN PEROXIDE; HYDROXYL RADICAL; MANGANESE SUPEROXIDE DISMUTASE; MATRIX PROTEIN; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) TRANSHYDROGENASE; NIMESULIDE; NITRIC OXIDE; PARACETAMOL; PEROXYNITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; THIOL GROUP; THYMINE; TROGLITAZONE; VALINE;

CELL PROTECTION; CELL STRESS; DNA MODIFICATION; DRUG MEGADOSE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; KNOCKOUT MOUSE; LIVER TOXICITY; LOW DRUG DOSE; MITOCHONDRIAL TOXICITY; MITOCHONDRION; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; TOXICITY TESTING; TOXICOKINETICS; TRANSGENICS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT; MITOCHONDRIA; OXIDATIVE STRESS; PHARMACEUTICAL PREPARATIONS; SUPEROXIDE DISMUTASE;

EID: 54049115421     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.08.002     Document Type: Review

References (77)

1. Wallace K.B., and Starkov A.A. Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 353-388
2. Amacher D.E. Drug-associated mitochondrial toxicity and its detection. Curr. Med. Chem. 12 (2005) 1829-1839
3. Chan K., et al. Drug-induced mitochondrial toxicity. Expert Opin. Drug Metab. Toxicol. 1 (2005) 655-669
4. Kass G.E.N. Mitochondrial involvement in drug-induced hepatic injury. Chem. Biol. Interact. 163 (2006) 145-159
5. Scatena R., et al. The role of mitochondria in pharmacotoxicology: a re-evaluation of an old, newly emerging topic. Am. J. Physiol. (Cell Physiol.) 293 (2007) C12-C21
6. Wallace K.B. Mitochondrial off targets of drug therapy. Trends Pharmacol. Sci. 29 (2008) 361-366
7. Wagner B.K., et al. Large-scale chemical dissection of mitochondrial function. Nat. Biotechnol. 26 (2008) 343-351
8. Xu J.J., et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105 (2008) 97-105
9. Rossignol R., et al. Mitochondrial threshold effects. Biochem. J. 370 (2003) 751-762
10. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 552 (2003) 335-344
11. Orrenius S., et al. Mitochondrial oxidative stress: implications for cell death. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 143-183
12. Armstrong J.S. The role of the mitochondrial permeability transition in cell death. Mitochondrion 6 (2006) 225-234
13. Chipuk J.E., et al. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Different. 13 (2006) 1396-1402
14. Kroemer G., et al. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87 (2007) 99-163
15. Boelsterli U.A., and Lim P.L.K. Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity?. Toxicol. Appl. Pharmacol. 220 (2007) 92-107
16. Dykens J.A., and Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12 (2007) 777-785
17. Dykens J.A., et al. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 7 (2007) 161-175
18. Boelsterli U.A., and Lee Y.H. Development of animal models of drug-induced mitochondrial toxicity. In: Dykens J.A., and Will Y. (Eds). Drug-Induced Mitochondrial Dysfunction (2008), Wiley & Sons, Inc. 539-554
19. Gunawan B., et al. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 131 (2006) 165-178
20. Latchoumycandane C., et al. Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. Hepatology 45 (2007) 412-421
21. Bajt M.L., et al. Mitochondrial Bax translocation accelerates DNA fragmentation and cell necrosis in a murine model of acetaminophen hepatotoxicity. J. Pharmacol. Exp. Ther. 324 (2008) 8-14
22. Oliveira P.J., and Wallace K.B. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats-relevance for mitochondrial dysfunction. Toxicology 220 (2006) 160-168
23. Dixit R., and Boelsterli U.A. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Disc. Today 12 (2007) 336-342
24. Suzuki S., et al. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res. Clin. Pract. 45 (1999) 161-168
25. Rolo A.P., and Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 212 (2006) 167-178
26. Choksi K.B., and Papaconstantinou J. Age-related alterations in oxidatively damaged proteins of mouse heart mitochondrial electron transport chain complexes. Free Radic. Biol. Med. 44 (2008) 1795-1805
27. Wallace D.C. Mouse models for mitochondrial disease. Am. J. Med. Genet. 106 (2001) 71-93
28. Nakada K., et al. Mito-mice: animal models for mitochondrial DNA-based diseases. Sem. Cell Dev. Biol. 12 (2001) 459-465
29. Pinkert C.A., and Trounce I.A. Production of transmitochondrial mice. Methods 26 (2002) 348-357
30. Fan W.W., et al. A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations. Science 319 (2008) 958-962
31. Okado-Matsumoto A., and Fridovich I. Subcellular distribution of superoxide dismutase (SOD) in rat liver. Cu, Zn-SOD in mitochondria. J. Biol. Chem. 276 (2001) 38388-38393
32. Li Q., et al. A possible cooperation of SOD1 and cytochrome c in mitochondria-dependent apoptosis. Free Radic. Biol. Med. 40 (2006) 173-181
33. Fridovich I. Superoxide radical and superoxide dismutases. Ann. Rev. Biochem. 64 (1995) 97-112
34. 2 in cells and thereby their biological state. Free Radic. Biol. Med. 41 (2006) 1338-1350
35. Beyer W., et al. Superoxide dismutases. Prog. Nucleic Acid Res. Mol. Biol. 40 (1991) 221-253
36. Huang T.T., et al. The use of transgenic and mutant mice to study oxygen free radical metabolism. Ann. N.Y. Acad. Sci. 893 (1999) 95-112
37. Chaiswing L., et al. Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute Adriamycin-induced mitochondrial toxicity. Mol. Cancer Ther. 4 (2005) 1056-1064
38. Jones S.P., et al. Role of intracellular antioxidant enzymes after in vivo myocardial ischemia and reperfusion. Am. J. Physiol. (Heart Circ. Physiol.) 284 (2003) H277-H282
39. Goto H., et al. Endothelial MnSOD overexpression prevents retinal VEGF expression in diabetic mice. Biochem. Biophys. Res. Commun. 366 (2008) 814-820
40. Silva J.P., et al. SOD2 overexpression: enhanced mitochondrial tolerance but absence of effect on UCP activity. EMBO J. 24 (2005) 4061-4070
41. 2 formation. Free Radic. Biol. Med. 42 (2007) 1465-1469
42. Gardner R., et al. Why does SOD overexpression sometimes enhance, sometimes decrease, hydrogen peroxide production? A minimalist explanation. Free Radic. Biol. Med. 32 (2002) 1351-1357
43. Epperly M.W., et al. Overexpression of manganese superoxide dismutase (MnSOD) in whole lung or alveolar type II cells of MnSOD transgenic mice does not provide intrinsic lung irradiation protection. Int. J. Cancer (Radiat. Oncol. Invest.) 96 (2001) 11-21
44. Vasilaki A., et al. Genetic modification of the manganese superoxide dismutase/glutathione peroxidase 1 pathway influences intracellular ROS generation in quiescent, but not contracting, skeletal, muscle cells. Free Radic. Biol. Med. 41 (2006) 1719-1725
45. Huang T.T., et al. Genetic modification of prenatal lethality and dilated cardiomyopathy in Mn superoxide dismutase mutant mice. Free Radic. Biol. Med. 31 (2001) 1101-1110
46. Lebovitz R.M., et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9782-9787
47. Li Y., et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat. Genet. 11 (1995) 376-381
48. Melov S., et al. Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc. Natl. Acad. Sci. U. S. A 96 (1999) 846-851
49. Huang T.T., et al. Genetic modifiers of the phenotype of mice deficient in mitochondrial superoxide dismutase. Hum. Mol. Genet. 15 (2006) 1187-1194
50. Hinerfeld D., et al. Endogenous mitochondrial oxidative stress: neurodegeneration, proteomics analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J. Neurochem. 88 (2004) 657-667
51. Morten K.J., et al. Mitochondrial reactive oxygen species in mice lacking superoxide dismutase 2. J. Biol. Chem. 281 (2006) 3354-3359
52. Ikegami T., et al. Model mice for tissue-specific deletion of the manganese superoxide dismutase (MnSOD) gene. Biochem. Biophys. Res. Commun. 296 (2002) 729-736
53. Xia X.G., et al. Pol II-expressed shRNA knocks down Sod2 gene expression and causes phenotypes of the gene knockout in mice. PLoS Genet. 2 (2006) 73-80
54. Kalueff A.V., et al. The developing use of heterozygous mutant mouse models in brain monoamine transporter research. Trends Pharmacol. Sci. 28 (2007) 122-127
55. Van Remmen H., et al. Characterization of the antioxidant status of the heterozygous manganese superoxide dismutase knockout mouse. Arch. Biochem. Biophys. 363 (1999) 91-97
56. Kokoszka J.E., et al. Increased mitochondrial oxidative stress in the Sod2+/- mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2278-2283
57. Williams M.D., et al. Increased oxidative damage is correlated to mitochondrial function in heterozygous manganese dismutase knockout mice. J. Biol. Chem. 273 (1998) 28510-28515
58. -/+ mice. Free Radic. Biol. Med. 36 (2004) 542-554
59. Murakami K., et al. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J. Neurosci. 18 (1998) 205-213
60. Van Remmen H., et al. Knockout mice heterozygous for Sod2 show alterations in cardiac mitochondrial function and apoptosis. Am. J. Physiol. (Heart Circ. Physiol.) 281 (2001) H1422-H1432
61. Van Remmen H., et al. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol. Genomics 16 (2003) 29-37
62. Van Remmen H., et al. Multiple deficiencies in antioxidant enzymes in mice result in a compound increase in sensitivity to oxidative stress. Free Radic. Biol. Med. 36 (2004) 1625-1634
63. Cortopassi G., and Wang E. Modelling the effects of age-related mtDNA mutation accumulation: complex I deficiency, superoxide and cell death. Biochim. Biophys. Acta 1271 (1995) 171-176
64. Boelsterli U.A. Idiosyncratic drug hepatotoxicity revisited: new insights from mechanistic toxicology. Toxicol. Mech. Methods 13 (2003) 3-20
65. Boelsterli, U.A. and Kashimshetty, R. (in press) Idiosyncratic drug-induced liver injury: mechanisms and susceptibility factors. In Hepatic and Gastrointestinal Toxicology, (vol. 10) (Roth, R.A. and Ganey, P.E., eds,) Elsevier
66. Adam-Vizi V., and Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci. 27 (2006) 639-645
67. +/- mice. Free Radic. Biol. Med. 40 (2006) 420-429
68. Ong M.M.K., et al. Troglitazone-induced hepatic necrosis in an animal model of silent mitochondrial abnormalities. Toxicol. Sci. 97 (2007) 205-213
69. +/- mice: two-stage oxidative injury. Toxicol. Appl. Pharmacol 231 (2008) 43-51
70. New L.S., et al. Pharmacokinetic study of intraperitoneally administered troglitazone in mice using UPLC/MS/MS. Rapid Commun. Mass Spectrom. 21 (2007) 982-988
71. Zelko I.N., et al. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic. Biol. Med. 33 (2002) 337-349
72. Shimoda-Matsubayashi S., et al. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem. Biophys. Res. Commun. 226 (1996) 561-565
73. Nahon P., et al. Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death. Clin. Gastroenterol. Hepatol. 3 (2005) 292-298
74. Huang Y.S., et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol. 47 (2007) 128-134
75. Lynn S., et al. Selective neuronal vulnerability and inadequate stress response in superoxide dismutase mutant mice. Free Radic. Biol. Med. 38 (2005) 817-828
76. Strassburger M., et al. Heterozygous deficiency of manganese superoxide dismutase results in severe lipid peroxidation and spontaneous apoptosis in murine myocardium in vivo. Free Radic. Biol. Med. 38 (2005) 1458-1470
77. +/- mice, an animal model of discreet mitochondrial oxidant stress. Proteomics 8 (2008) 555-568